Web Results

accessmedicine.mhmedical.com/content.aspx?sectionid=161351108

The liver is a major site for drug metabolism. The goal of metabolism is to produce metabolites that are polar or charged, and can be eliminated by the kidney. Lipid-soluble agents are metabolized by the liver using two general sets of reactions, called phase I and phase II. + +

bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bcp.12086

The contribution of the kidney to drug metabolic clearance is generally predicted to be less than that of liver given the lower organ weight and microsome yield of the kidneys 2. However, in vitro – in vivo extrapolation of kinetic data is not possible in the absence of a valid model of renal metabolic clearance.

bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.12086

the metabolism of arachidonic acid and eicosanoids are expressed in human kidney,CYP 4A11,4F2,4F8,4F11 and 4F12.With the current limited evidence of drug substrates for human renal P450s drug–endobiotic interactions arising from inhibition of renal P450s,

cjasn.asnjournals.org/content/13/12/1897

Patients are exposed to numerous prescribed and over-the-counter medications. Unfortunately, drugs remain a relatively common cause of acute and chronic kidney injury. A combination of factors including the innate nephrotoxicity of drugs, underlying patient characteristics that increase their risk for kidney injury, and the metabolism and pathway of excretion by the kidneys of the various ...

academic.oup.com/qjmed/article/93/3/147/1525558

The majority of these drugs, or their metabolites, are excreted via the kidney. While some substances may be directly nephrotoxic, a number of other mechanisms are also involved. To achieve their recreational effects these drugs must cross the blood‐brain barrier and many are highly lipid‐soluble; this results in high volumes of ...

ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.757

Apart from the well‐recognized effects of kidney disease on renal drug clearance, there is a growing body of evidence demonstrating that the nonrenal clearances of drugs eliminated by certain transporters and drug‐metabolizing enzymes are decreased in patients with chronic kidney disease (CKD).

fdahealthnews.com/stories/566140449-fda-approves-first-drug-to-treat-rare...

Patients can experience progressive kidney damage, which can lead to kidney failure and the need for dialysis (a treatment that purifies the blood). As kidney function worsens, oxalate can build up and damage other organs, including the heart, bones and eyes.

www.kidneynews.org/kidney-news/special-sections/geriatric-nephrology/drug...

Chronic kidney disease (CKD) is a prevalent disease in the United States that disproportionately affects the elderly. The national prevalence is approximately 15 percent and reaches nearly 50 percent in adults aged 70 years and older ().CKD stages 1 and 2 are characterized by a GFR >60 mL/min/1.73 m 2, and dose adjustments are usually indicated only for drugs that have a narrow therapeutic ...

www.msdmanuals.com/home/drugs/administration-and-kinetics-of-drugs/drug...

All drugs are eventually eliminated from the body. They may be eliminated after being chemically altered (metabolized), or they may be eliminated intact. Most drugs, particularly water-soluble drugs and their metabolites, are eliminated largely by the kidneys in urine. Therefore, drug dosing depends largely on kidney function.

www.wfsahq.org/components/com_virtual_library/media/f7d652ac786de56a4a...

Many sites in the body are involved in drug metabolism including the gut wall, lungs, kidney and plasma. However, the liver is the most metabolically active tissue per unit weight and is thus responsible for the majority of drug metabolism. Other factors responsible for its contribution include